Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life
Abstract
Despite some approvals of antibody-drug conjugates for cancer therapy, their clinical success rate is unsatisfactory because of very small therapeutic windows, influenced by on-target and off-target toxicities of conjugate and liberated toxin. Additional formats with systematically investigated molecular parameters must therefore be explored to increase their therapeutic window. Here we focused on the effective molecular weight. To generate...
Paper Details
Title
Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life
Published Date
Nov 1, 2020
Volume
327
Pages
186 - 197
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History